Top

Published in:

01-11-2004 | Original Article

Generation of human tumor-specific CTLs in HLA-A2.1–transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors

Authors: Angelos D. Gritzapis, Nectaria N. Sotiriadou, Michael Papamichail, Constantin N. Baxevanis

Published in: Cancer Immunology, Immunotherapy | Issue 11/2004

Abstract

HER-2/neu oncoprotein is overexpressed in a variety of human tumors and is associated with malignant transformation and aggressive disease. Due to its overexpression in tumor cells and because it has been shown to be immunogenic, this protein represents an excellent target for T-cell immunotherapy. Peptide extracts derived from primary HLA-A*0201-positive (+) HER-2/neu ⁺ human tumors by acid elution (acid cell extracts (ACEs)) were tested for their capacity to elicit in HLA-A*0201 transgenic mice, cytotoxic T lymphocytes (CTLs) lysing HLA-A*0201⁺ HER-2/neu ⁺ tumor cells. Injections of ACE in transgenic mice induced CTLs capable of specifically lysing HER-2/neu ⁺ tumor cell lines (also including the original HER-2/neu ⁺ primary tumor cells from which the ACEs were derived) in an HLA-A*0201–restricted fashion. Adoptive transfer of ACE-induced CTLs was sufficient to significantly prolong survival of SCID mice inoculated with HLA-A*0201⁺ HER-2/neu ⁺ human tumor cell lines. Cytotoxicity of such ACE-induced CTL lines was directed, at least as detected herein, also against the HER-2/neu peptides HER-2 (9₃₆₉) and HER-2 (9₄₃₅) demonstrating the immunodominance of these epitopes. HER-2 peptide–specific CTLs generated in the HLA-A*0201–transgenic mice, upon peptide immunization, lysed in vitro HER-2/neu ⁺ human tumor cell lines in an HLA-A*0201–restricted manner and, when adoptively transferred, conferred sufficient protection in SCID mice inoculated with the same human tumor cell lines as above. However, CTLs induced by ACEs displayed enhanced efficacy in the therapy of xenografted SCID mice compared with the HER-2 peptide–specific CTLs (i.e., HER-2 [9₃₆₉] or HER-2 [9₄₃₅]). Even by administering mixtures of CTLs specific for each of these peptides, the prolongation of survival achieved was still inferior compared with that obtained with ACE-induced CTLs. This suggested that additional epitopes may contribute to the immunogenicity of such tumor-derived ACEs. Thus, immunization with ACEs from HER-2/neu ⁺ primary tumor cells appears to be an effective approach to generate multiple and potent CTL-mediated immune responses against HER-2/neu ⁺ tumors expressing the appropriate HLA allele(s). By screening ACE-induced CTL lines with synthetic peptides encompassing the HER-2/neu sequence, it is feasible to identify immunodominant epitopes which may be used in mixtures as vaccines with enhanced efficacy in both the prevention and therapy of HER-2/neu ⁺ malignancies.

Houbiers JG, Nijman HW, Ven der Brug SH, Drijfrout JW, Kenemans P, Van de Velde CJ, Brand A, Momburg F, Kast WM, Melief CJ (1993) In vitro induction of human cytotoxic T lymphocyte responses against peptide of mutant and wild-type p53. Eur J Immunol 23:2072–2078PubMed

Stevanovic S, Schild H (1999) Quantitative aspects of T cell activation-peptide generation and editing by MHC class I molecules. Semin Immunol 11:375–384CrossRefPubMed

Berke G (1994) The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu Rev Immunol 12:735–773CrossRefPubMed

Wang RF (1999) Human tumor antigens: implications for cancer vaccine development. J Mol Med 77:640–655CrossRefPubMed

Anichini A, Mortarini R, Maccalli C, Squarcina P, Fleischhauer K, Mascheroni L, Parmiani G (1996) Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1 restricted immune repertoire to melanoma. J Immunol 156:208–213PubMed

Knutson KL, Schiffman K, Disis ML (2001) Immunization with a helper peptide vaccine penetrates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107:477–484PubMed

Van Elsas A, Nijman HW, Van der Minne CE, Mourer JS, Kast WM, Melief CJ, Schrier PI (1995) Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21^ras peptide represented by HLA-A*0201. Int J Cancer 61:389–395PubMed

Pawelec G (1999) Tumor escape from the immune response: the last hurdle for successful immunotherapy of cancer? Cancer Immunol Immunother 48:343–349PubMed

Fields RC, Shimizu K, Mule JJ (1998) Murine dendritic cells pulsed with whole tumor lysates mediated potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 95:9482–9487CrossRefPubMed

10.

Goddard RV, Prentice AG, Copplestone JA, Kaminski ER (2001) Generation in vitro of B- cell chronic lymphocytic leukemia-proliferative and specific HLA- class II restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumor cell lysate. Clin Exp Immunol 126:16–23CrossRefPubMed

11.

Graner MW, Zeng Y, Fong H, Katsanis E (2003) Tumor-derived chaperone-rich lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother 52:226–234PubMed

12.

Greenberg PD (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281–355PubMed

13.

Holth L, Zehle-Risser C, Gander H, Papesh C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL, Coggin JH Jr, Thurnher M (2002) Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8:3369–3376PubMed

14.

Schnurr M, Scholz C, Rothenfusser S, Galambos P, Daner M, Robe J, Enders S, Eigler A (2002) Apoptosis pancreatic tumor cells are superior to cell lysates in promoting cross- priming of cytotoxic T cells and activate NK and γδ cells. Cancer Res 62:2347–2352PubMed

15.

Vegh Z, Mazumder A (2003) Generation of tumor cell lysate-loaded dendritic cells preprogrammed for IL-12 production and augmented T cell response. Cancer Immunol Immunother 52:67–79PubMed

16.

Wen YJ, Min R, Tricot G, Barlogie B, Yi W (2002) Tumor lysate-specific cytotoxic T lymphocytes in multiple-myeloma: promising new effector cells for immunotherapy. Blood 99:3180–3287CrossRef

17.

Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332PubMed

18.

Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M (2000) Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 164:3902–3912PubMed

19.

Baxevanis CN, Gritzapis AD, Tsitsilonis OE, Katsoulas HL, Papamichail M (2002) HER-2/neu-derived epitopes are also recognized by cytotoxic CD3+CD56+(natural killer T) lymphocytes. Int J Cancer 98:864–872CrossRefPubMed

20.

Berger U, Wilson P, Thethi S, McClelland RA, Greene GL, Coombes RC (1989) Comparison of an immunocytochemical assay for progesterone receptor with a biochemical method of measurement and immunocytochemical examination of the relationship between progesterone and estrogen receptors. Cancer Res 49:5176–5179PubMed

21.

Sotiropoulou PA, Perez SA, Iliopoulou EG, Missitzis I, Voelter V, Echner H, Baxevanis CN, Papamichail M (2003) Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumors. Br J Cancer 89:1035–1061CrossRefPubMed

22.

Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Pevarneau B (1997) HLA-A*0201 restricted education and cytolytic activity of CD8+ T lymphocytes from β2m-HLA-A*0201 monochain transgenic, H-2Db, β2m double knock out mice. J Exp Med 185:2043–2051PubMed

23.

Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109–2117PubMed

24.

Rongcun Y, Salazar-Onfray F, Charo J, Malmberg J-J, Ervin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R (1999) Identification of new HER-2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163:1037–1044PubMed

25.

Kirkin AF, Thor Straten P, Hansen MR, Barfoed A, Dzhandzhugazyan KN, Zeuthen J (1999) Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected high immunogenic melanoma cell clones. Cancer Immunol Immunother 48:239–246

26.

Baxevanis CN, Dedoussis GVZ, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M (1994) Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 74:1275–1282PubMed

27.

Nair SK, Boczkowski D, Smyder D, Gilboa E (1997) Antigens-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 27:589–597PubMed

28.

Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K (2001) Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol 31:3261–3270CrossRefPubMed

29.

Perez SA, Sotiropoulou PA, Sotiriadou NN, Mamalaki A, Gritzapis AD, Echner H, Voelter N, Pawelec G, Papamichail M, Baxevanis CN (2002) HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4+ T cell clones. Cancer Immunol Immunother 50:615–624PubMed

30.

Riddell SR, Elliot M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, Lipton SD, Overell RW, Reynolds TC, Corey L, Greenberg PD (1996) T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2:216–233PubMed

31.

Sotiropoulou PA, Perez SA, Voelter V, Echner H, Missitzis I, Tsavaris NB, Papamichail M, Baxevanis CN (2003) Natural CD8(+) T-cell responses against MHC class I epitopes of the HER-2/neu oncoprotein in patients with epithelial tumors. Cancer Immunol Immunother 52:771–780CrossRefPubMed

32.

Robbins PF, El-Gamil M, Li FY, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA (1995) Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 154:5944–5950PubMed

33.

Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML Cheever M, Sherman LA (1997) Identification of HER-2/neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Hum Immunol 52:109–118CrossRefPubMed

34.

Schneider J, Gilbert SC, Blanchard TJ, Hanke Y, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AV (1998) Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4:397PubMed

35.

Toes RE, Hoeben RC, van der Voort EI, Ressing ME, van der Eb AJ, Melief CJ, Offringa R (1997) Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci U S A 94:14660–14666CrossRefPubMed

36.

Thomson SA, Sherritt MA, Medvezky J, Elliott SL, Moss DJ, Fernando GJ, Brown LE, Suhrbier A (1998) Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J Immunol 160:1717–1722PubMed

37.

Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo ID Jr (1996) DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 10:1122

38.

Ishioka GY, Fikes J, Hermanson G, Livingston B, Crimi C, Qin M, del Guercio MF, Oseroff C, Dahlberg C, Alexander J, Chesnut RW, Sette A (1999) Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol 162:3915–3925PubMed

39.

Mateo L, Gardner J, Chen Q, Schmidt C, Down M, Elliot SL, Pye SJ, Firat H, Lemonnier FA, Cebon J, Suhrbier A (1999) An HLA-A2 polypeptide vaccine for melanoma immunotherapy. J Immunol 163:4058–4063PubMed

40.

Ercolini AM, Machiels J-PH, Chen YC, Slansky JE, Gielden M, Reilly RT, Jaffee EM (2003) Identification and characterization of the immunodominant rat HER- 2/neu MHC class I epitope presented by spontaneous mammary tumors from HER- 2/neu-transgenic mice. J Immunol 170:4273–4280PubMed

Title: Generation of human tumor-specific CTLs in HLA-A2.1–transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors
Authors: Angelos D. Gritzapis
Nectaria N. Sotiriadou
Michael Papamichail
Constantin N. Baxevanis
Publication date: 01-11-2004
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 11/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-004-0541-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2004

Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells

Autologous tumor vaccines processed to express α-gal epitopes: a practical approach to immunotherapy in cancer

Virosomes as new carrier system for cancer vaccines

Anti-idiotype responses abrogate anti-CD4–induced tolerance to a tumor-specific antigen and promote systemic tumor immunity

Cancer gene therapy: new horizons in the East

Lower percentages of monocytes with CD80, CD86 and HLA-DR molecule expression in pediatric cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer